Newron Pharmaceuticals SpA P/E 2025

Newron Pharmaceuticals SpA Aktienanalyse

What does Newron Pharmaceuticals SpA do?

Newron Pharmaceuticals SpA is an international biopharmaceutical company specializing in the development of novel products for the treatment of central nervous system (CNS) disorders. The company is headquartered in Italy and is listed on the SIX Swiss Exchange. The history of Newron Pharmaceuticals SpA dates back to 1996 when it was founded by a team of experienced pharmaceutical experts. Since then, the company has become a leading player in the development of therapies for rare neurological disorders. The focus is particularly on diseases such as Parkinson's and Rett syndrome, as well as other neurological disorders. Newron Pharmaceuticals SpA's business model is based on the research and development of novel drugs in the field of the central nervous system. The company typically conducts research and development in its own laboratories and collaborates closely with external experts and institutions to develop innovative therapies. The goal is to develop patient-oriented, innovative drugs and successfully bring them to market. The company has several product candidates in various stages of development, including Xadago® (Safinamide), an approved drug for the treatment of Parkinson's. Similarly, an orally administered drug is being tested in phase III of clinical development with the aim of improving motor symptoms in Parkinson's. Another important product candidate of Newron Pharmaceuticals SpA is Sarizotan, an innovative drug for the treatment of Rett syndrome, a rare neurological disease that primarily affects girls. The company has entered into a partnership with the American company Rett Syndrome Research Trust (RSRT) to promote further development of the drug. In addition to researching and developing new drugs, Newron also actively works on advancing existing treatment approaches. For example, collaborations with academic institutions are used to incorporate new knowledge from the fields of molecular biology and genetics to further expand existing therapeutic approaches. The company follows an integrative approach, focusing on collaboration between research and development teams, clinical experts, patient organizations, and regulatory authorities. The goal is to treat patients with novel and effective therapies. Overall, Newron Pharmaceuticals SpA is an internationally operating biopharmaceutical company dedicated to researching and developing novel therapies in the field of the central nervous system. Through its innovative research and development activities and close collaboration with experts, institutions, and patient organizations, the company significantly contributes to the advancement of treatment options for neurological disorders. Newron Pharmaceuticals SpA ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Newron Pharmaceuticals SpA's P/E Ratio

The Price to Earnings (P/E) Ratio of Newron Pharmaceuticals SpA is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Newron Pharmaceuticals SpA's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Newron Pharmaceuticals SpA is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Newron Pharmaceuticals SpA’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Newron Pharmaceuticals SpA stock

What is the price-to-earnings ratio of Newron Pharmaceuticals SpA?

The price-earnings ratio of Newron Pharmaceuticals SpA is currently -6.69.

How has the price-earnings ratio of Newron Pharmaceuticals SpA changed compared to last year?

The price-to-earnings ratio of Newron Pharmaceuticals SpA has increased by -207.73% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Newron Pharmaceuticals SpA high compared to other companies?

Yes, the price-to-earnings ratio of Newron Pharmaceuticals SpA is high compared to other companies.

How does an increase in the price-earnings ratio of Newron Pharmaceuticals SpA affect the company?

An increase in the price-earnings ratio of Newron Pharmaceuticals SpA would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Newron Pharmaceuticals SpA affect the company?

A decrease in the price-earnings ratio of Newron Pharmaceuticals SpA would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Newron Pharmaceuticals SpA?

Some factors that influence the price-earnings ratio of Newron Pharmaceuticals SpA are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Newron Pharmaceuticals SpA pay?

Over the past 12 months, Newron Pharmaceuticals SpA paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Newron Pharmaceuticals SpA is expected to pay a dividend of 0 EUR.

What is the dividend yield of Newron Pharmaceuticals SpA?

The current dividend yield of Newron Pharmaceuticals SpA is .

When does Newron Pharmaceuticals SpA pay dividends?

Newron Pharmaceuticals SpA pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Newron Pharmaceuticals SpA?

Newron Pharmaceuticals SpA paid dividends every year for the past 0 years.

What is the dividend of Newron Pharmaceuticals SpA?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Newron Pharmaceuticals SpA located?

Newron Pharmaceuticals SpA is assigned to the 'Health' sector.

Wann musste ich die Aktien von Newron Pharmaceuticals SpA kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Newron Pharmaceuticals SpA from 1/31/2025 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 1/31/2025.

When did Newron Pharmaceuticals SpA pay the last dividend?

The last dividend was paid out on 1/31/2025.

What was the dividend of Newron Pharmaceuticals SpA in the year 2024?

In the year 2024, Newron Pharmaceuticals SpA distributed 0 EUR as dividends.

In which currency does Newron Pharmaceuticals SpA pay out the dividend?

The dividends of Newron Pharmaceuticals SpA are distributed in EUR.